NCT01930994

Brief Summary

A cross-sectional study to compare pharmacokinetics of Sino-implant (II) during four years of used and Jadelle during five years of use by Kenyan women.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2013

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 21, 2013

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 29, 2013

Completed
3 days until next milestone

Study Start

First participant enrolled

September 1, 2013

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

October 14, 2013

Status Verified

October 1, 2013

Enrollment Period

3 months

First QC Date

August 21, 2013

Last Update Submit

October 11, 2013

Conditions

Keywords

LNG: LevonorgestrelMSI: Marie Stopes InternationalMSK: Marie Stopes KenyaPK: Pharmacokinetic

Outcome Measures

Primary Outcomes (1)

  • Total and Free LNG concentrations in Jadelle users at Four Years and Sino-implant users at Five Years

    Total and free LNG plasma concentrations measured at four years of Sino-implant (II)use and at five years of Jadelle use

    6 months

Secondary Outcomes (3)

  • Total and Free LNG concentrations at Four Years of Jadelle and Sino-implant Use

    6 months

  • Total and free LNG plasma concentration-time profiles at 4 years following Sino-implant (II) and at over 5 years following Jadelle insertion

    6 months

  • SHBG serum concentration-time profile over 4 years following Sino-implant (II) and over 5 years following Jadelle insertion.

    6 months

Study Arms (6)

Cohort 1

Twenty Sino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 6-month insertion anniversary.

Cohort 2

TwentySino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 12-month insertion anniversary;

Cohort 3

Twenty Sino-implant (II) and twenty Jadelle) users enrolled 1-3 months before their 24-month insertion anniversary

Cohort 4

Twenty Sino-implant(II) and twenty Jadelle users enrolled 1-3 months before their 36-month insertion anniversary;

Cohort 5

Forty Sino-implant (II) and forty Jadelle users enrolled 1-3 months before their 48-month insertion anniversary;

Cohort 6

Forty Jadelle users enrolled 2-6 months before their 60-month insertion anniversary.

Eligibility Criteria

Age18 Years - 44 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Women between the ages of 18 and 44 who have received contraceptive implants from the Marie Stopes Kenya Eastleigh clinic and MSK mobile clinics in the Nairobi area.

You may qualify if:

  • Have a Sino-implant (II) or Jadelle implant set in place, confirmed by physical exam;
  • Have a confirmed contraceptive implant insertion date consistent with the criteria for the cohort she is to be enrolled in;
  • Be aged between 18 and 44 years, inclusive;
  • Not wish to become pregnant in the next six months;
  • Not desire implant removal within the next six months.
  • Be able to understand the information given to them and to make personal decisions on whether to participate or not in the study;
  • Consent to participation, and sign an informed consent form;
  • Agree and be able to return to the clinic for the second study visit.

You may not qualify if:

  • Use of rifampicin, and/or anticonvulsants (barbiturates, phenytoin, phenobarbital, carbamazepine, oxcarbazepine, primidone, topiramate), and/or herbal products containing St. John's wort (Hypericum perforatum), by self-report;7
  • Use of medications containing LNG or other hormones that impact LNG or SHBG disposition, e.g. treatment with LNG or oral contraceptives for bleeding disturbances, by self-report;
  • Use of anti-retroviral drugs, by self-report;
  • Any condition (social or medical) which in the opinion of the Investigator would make study participation unsafe, would interfere with adherence to study requirements or complicate data interpretation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Marie Stopes Kenya Eastleigh Clinic

Nairobi, Kenya

Location

Study Officials

  • Mark Ayallo, MD

    Marie Stopes Kenya

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 21, 2013

First Posted

August 29, 2013

Study Start

September 1, 2013

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

October 14, 2013

Record last verified: 2013-10

Locations